Processing your request


please wait...

Case Page

 

Case Status:    DISMISSED    
On or around 06/23/2020 (Notice of voluntarily dismissal)

Filing Date: April 13, 2020

According to the Complaint, Mylan N.V. is a global pharmaceutical company.

On July 29, 2019, Mylan N.V.’s Board of Directors caused the Company to enter into a Business Combination Agreement (the “Agreement”) with Pfizer Inc. Pursuant to the terms of the Agreement, Newco and Mylan will combine their businesses, and Mylan shareholders will receive one share of Newco common stock for each Mylan ordinary share. Following the consummation of the Proposed Transaction, Mylan shareholders will hold 43% of the fully diluted outstanding shares of Newco common stock.

On February 13, 2020, Defendants filed a proxy statement with the United States Securities and Exchange Commission in connection with the Proposed Transaction, which recommends that the Company’s stockholders vote to approve the Proposed Transaction at a special meeting of stockholders scheduled for April 27, 2020. The Complaint alleges that the Proxy Statement omits material information with respect to the Proposed Transaction, which renders the Proxy Statement false and misleading. Specifically, the Complaint alleges that the Proxy Statement fails to disclose: (i) all line items used to calculate (a) Adjusted EBITDA and (b) Unlevered Free Cash Flow; and (ii) a reconciliation of all non-GAAP to GAAP metrics.

This case was voluntarily dismissed on June 23, 2020.

COMPANY INFORMATION:

Sector: Healthcare
Industry: Biotechnology & Drugs
Headquarters: United Kingdom

SECURITIES INFORMATION:

Ticker Symbol: MYL
Company Market: NASDAQ
Market Status: Public (Listed)

About the Company & Securities Data


"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
COURT: D. Delaware
DOCKET #: 20-CV-00504
JUDGE: Hon. Richard G. Andrews
DATE FILED: 04/13/2020
CLASS PERIOD START: 07/29/2019
CLASS PERIOD END: 04/13/2020
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Rigrodsky & Long, P.A. (Wilmington)
  2. RM Law, P.C. (Berwyn)
No Document Title Filing Date
—Reference Complaint Complaint Related Data is not available
—Related District Court Filings Data is not available